Clinical Trial Update: A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST [NA]

View source ↗

Summary

This clinical trial update concerns the evaluation of dasatinib for efficacy and safety in patients with refractory metastatic gastrointestinal stromal tumor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Gastrointestinal Stromal Tumor | NA | Status: UNKNOWN